Skip to content
Bored Studies
RecruitingPhase 3

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Hoffmann-La Roche · NCT07177352

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50–90 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
80000
US sites recruiting
68
Study start
July 2, 2025
Record last updated
October 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Being studied: No Intervention

Conditions: Alzheimers Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
  • Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study

Exclusion Criteria

  • Dependency in basic activities of daily living (bADLs) due to cognitive impairment
  • Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
  • Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
  • History of severe, clinically significant central nervous system trauma
  • Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
  • For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary

Recruiting US locations

+ 8 more on the official record.

Study contacts (from the official record)

  • Reference Study ID Number: WP45722 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
All neurology studies in Alabama →
Screening Study to Determine Individuals With Potential Trial… (NCT07177352) | Bored Studies